Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of normal saline (an isotonic solution of sodium chloride in water) and palonosetron, a selective serotonin 5-HT3 receptor antagonist. Normal saline serves as an intravenous fluid for hydration or as a vehicle for drug administration, while palonosetron is used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Palonosetron works by blocking 5-HT3 receptors both peripherally (in the gastrointestinal tract) and centrally (in the chemoreceptor trigger zone of the brain), thereby inhibiting the vomiting reflex triggered by serotonin release during emetogenic stimuli[6][8][9]. The combination may be used when palonosetron is administered intravenously diluted in normal saline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on normal saline + palonosetron.